Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
Top Cited Papers
- 29 July 2015
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (5), 428-437
- https://doi.org/10.1056/NEJMoa1411366
Abstract
BACKGROUND Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most tenosynovial giant-cell tumors. This observation has led to the discovery and clinical development of therapy targeting the CSF1 receptor (CSF1R). METHODS Using x-ray co-crystallography to guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps the kinase in the auto-inhibited conformation. We then conducted a multicenter, phase 1 trial in two parts to analyze this compound. In the first part, we evaluated escalations in the dose of PLX3397 that was administered orally in patients with solid tumors (dose-escalation study). In the second part, we evaluated PLX3397 at the chosen phase 2 dose in an extension cohort of patients with tenosynovial giant-cell tumors (extension study). Pharmacokinetic and tumor responses in the enrolled patients were assessed, and CSF1 in situ hybridization was performed to confirm the mechanism of action of PLX3397 and that the pattern of CSF1 expression was consistent with the pathological features of tenosynovial giant-cell tumor. RESULTS A total of 41 patients were enrolled in the dose-escalation study, and an additional 23 patients were enrolled in the extension study. The chosen phase 2 dose of PLX3397 was 1000 mg per day. In the extension study, 12 patients with tenosynovial giant-cell tumors had a partial response and 7 patients had stable disease. Responses usually occurred within the first 4 months of treatment, and the median duration of response exceeded 8 months. The most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema; adverse events rarely led to discontinuation of treatment. CONCLUSIONS Treatment of tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor volume in most patients.This publication has 20 references indexed in Scilit:
- Pigmented Villonodular Synovitis: Current Concepts About Diagnosis and ManagementFuture Oncology, 2013
- CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate CancerCancer Research, 2013
- Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibitionActa Neuropathologica, 2012
- Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) SignalingMolecular Medicine, 2012
- Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitisCurrent Opinion in Oncology, 2011
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to ChemotherapyCancer Discovery, 2011
- Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive SynovitidesThe American Journal of Surgical Pathology, 2007
- The 2.7 Å Crystal Structure of the Autoinhibited Human c-Fms Kinase DomainJournal of Molecular Biology, 2007
- Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesionsSkeletal Radiology, 2007
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsProceedings of the National Academy of Sciences of the United States of America, 2006